基于Varlilumab作为单一疗法并与PD-1抑制剂联用的先前临床数据经验，Celldex接下来也优化了另一种方案：开发了CD27&PD-L1双特异性抗体CDX-527，将CD27共刺激与PD-L1 / PD-1途径的阻断相结合，以帮助通过CD27共刺激来引发和激活抗肿瘤T细胞应答，同时防止PD- 1抑制信号破坏 ...

2019年2月15日 · 根据CD45RA、CD45RO、CD197（CCR7）、CD62L和CD27的差异表达，可以将CD4和CD8 T细胞的功能成熟阶段主要分为4个：初始T（TN）、中央记忆T（TCM）、效应记忆T（TEM）和终末效应T（TTE），除此之外，还有两个小亚群：干细胞记忆T（TSCM）和过渡记忆T（TTM）。 以上6个功能亚群，更详细的表面标记差异，参见下表： 补充说明. CD4＋T和CD8＋T之间，一些泛T细胞相关抗原的表达强度会有所差异，例如CD4＋T的CD5强度更 …

CD45RA − CD8 + memory T cells expressing CD27 produce both IL-2 and IFN-γ but lack immediate killing activity (therefore termed “memory”), while CD45RA − CD8 + T cells that are CD27 − produce mostly IFN-γ and TNF but not IL-2 and are capable of immediate cytotoxicity ex vivo (hence termed “effectors”) 17.

2023年1月8日 · Remarkably, CD3 + CD8 + CD27 + CD28 + and CD3 + CD8 + CD27-CD28-CD19 CART cells (expressing the CD19-specific CART cell receptor on 91.6 ± 0.1% % and 91.4 ± 0.1% of CD8 + T cells, respectively, Figure S7) killed CD19 + B cells (TM-LCL) with nearly identical efficacies over the entire range of effector to target (E:T) ratios tested, while no ...

基于cd27和cd45ra的表达差异vδ2t细胞又分为cd45ra + cd27 +（幼稚），cd45ra-cd27 +（中间，无记忆效应功能），cd45ra-cd27-（记忆效应）和cd45ra + cd27-（终末分化）四群。

2020年12月11日 · 通过CCR7和CD45RA，T细胞可分为四个主要亚群。 这些细胞被命名为初始细胞 (N)、中央记忆细胞 (CM)、效应记忆细胞 (EM)和重新表达CD45RA的终末分化效应记忆细胞 (TEMRA)，尽管体内也可能存在一些中间亚群。 除了这些标记物，CD27和CD28可进一步将T细胞亚群细分如下： •N (CCR7+、CD27++、CD28++、CD45RA+) •CM (CCR7+、CD27++、CD28+、CD45RA−) •EM (CCR7−、CD27+/−、CD28+/−、CD45RA−) •TEMRA (CCR7− …

Univariate and multivariate regression analyses showed that low levels of differentiated CD3 + CD27 - CD28 - T cells (23.3 ± 19.3% versus 35.1 ± 18.0%) were independently associated with OR. This association was even more pronounced when patients were stratified for complete remission (CR versus non-CR: 13.7 ± 11.7% versus 37.7 ± 17.4%, P=0.001).

CDX-527是Celldex开发的CD27和PD-L1的双特异性抗体，将CD27共刺激与PD-L1 / PD-1途径的阻断相结合。 临床前数据证明CDX-527在抗T细胞活化和抗肿瘤活性方面比抗PD-L1和抗CD27抗体更有效。

A substantial fraction (0.1–24%) of CD19 + CD27 + CD43 + events was highly positive for CD3 and dimly positive for CD19. Analysis of CD19 versus CD3 expression suggested that these cells were T lymphocytes that were incorrectly included in the CD19 + gate, and accounted for most CD5 + events in the gate ( Fig. 1, A–C ).

2023年1月9日 · CD3 + CD8 + T cells outperformed CD3 + CD4 + T cells 3- to 6-fold in terms of their ability to kill CD19 + target cells. Interpretation: Low frequency of differentiated CD3 + CD27-CD28-T cells at leukapheresis represents a novel pre-infusion blood biomarker predicting a favorable response to CART cell treatment in r/r DLBCL patients.